AstraZeneca Drops Seroquel XR Patent Suit; Biovail Will Not Sell Copy Until Patents Expire

Biovail Laboratories International SRL will not seek to sell its proposed generic version of AstraZeneca Pharmaceuticals LP’s atypical antipsychotic Seroquel XR (quetiapine fumarate) until after the patents covering the drug expire, Biovail said in a May 2 stipulation, ending the parties’ patent infringement litigation (AstraZeneca Pharmaceuticals LP v. Biovail Laboratories International SRL ).

In the stipulation entered in U.S. District Court for the District of New Jersey by Judge Joel A. Pisano, Biovail said it had changed its Paragraph IV certification—challenging the validity and enforceability of the AstraZeneca patents in suit—to a Paragraph III certification stating it would ...